PCL
MCID: PLS016
MIFTS: 50

Plasma Cell Leukemia (PCL)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Plasma Cell Leukemia

MalaCards integrated aliases for Plasma Cell Leukemia:

Name: Plasma Cell Leukemia 11 19 58 53 14 16 75
Plasma Cell Leukaemia 11 31 33
Leukemia, Plasma Cell 19 43 71
Plasmacytic Leukaemia 11 33
Plasma Cell Leukaemia Without Mention of Remission 33
Plasma Cell Leukaemia, Nos 33
Plasmacytic Leukemia 11
Leukemic Plasma Cell 33
Pcl 58

Characteristics:


Prevelance:

<1/1000000 (Europe) 58

Age Of Onset:

Adult,Elderly 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:9513
ICD9CM 34 203.1
MeSH 43 D007952
NCIt 49 C3180
SNOMED-CT 68 269630009
ICD10 31 C90.1
ICD10 via Orphanet 32 C90.1
UMLS via Orphanet 72 C0023484
Orphanet 58 ORPHA454714
ICD11 33 2048216430
UMLS 71 C0023484

Summaries for Plasma Cell Leukemia

Orphanet: 58 A rare plasma cell neoplasm characterized by peripheral plasmacytosis, usually with extensive and diffuse infiltration of the bone marrow, and monoclonal paraproteinemia. Neoplastic plasma cells may also be found in extramedullary sites, such as the liver or spleen, among others. Most cases present as primary plasma cell leukemia without previous diagnosis of myeloma. The condition can also represent leukemic transformation of plasma cell myeloma (secondary plasma cell leukemia). Clinical manifestations include lymphadenopathy, organomegaly, renal failure, bone marrow failure, and peripheral neuropathies. High serum levels of lactate dehydrogenase and beta2-microglobulin, as well as hypercalcemia (potentially leading to hypercalcemic crisis) are typically observed.

MalaCards based summary: Plasma Cell Leukemia, also known as plasma cell leukaemia, is related to plasmacytoma and macroglobulinemia. An important gene associated with Plasma Cell Leukemia is CCND1 (Cyclin D1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Toll-like receptor signaling pathway. The drugs Thalidomide and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and spleen, and related phenotypes are homeostasis/metabolism and neoplasm

GARD: 19 Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma that involves high levels of plasma cells circulating in the peripheral blood. The signs and symptoms of PCL include aggressive clinical features, such as extramedullary disease, bone marrow failure, advanced stage disease and expression of distinct immunophenotypic markers.

Disease Ontology: 11 A plasma cell neoplasm that is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.

Wikipedia: 75 Plasma cell leukemia (PCL) is a plasma cell dyscrasia, i.e. a disease involving the malignant... more...

Related Diseases for Plasma Cell Leukemia

Diseases related to Plasma Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 452)
# Related Disease Score Top Affiliating Genes
1 plasmacytoma 30.7 NCAM1 IRF4 IL6 CDKN2A CD38 CCND1
2 macroglobulinemia 30.6 SDC1 IL6 CD40
3 amyloidosis 30.4 MYOM2 IL6 IGHG1 CCND1
4 colonic benign neoplasm 30.4 IL6 CDKN2A CD44 CCND1
5 myeloma, multiple 30.3 SDC1 NSD2 NCAM1 MYOM2 MIR181A1 ITGB1
6 pfeiffer syndrome 30.3 NCAM1 MAF FGFR3 CD40
7 plasma cell neoplasm 30.2 SDC1 NCAM1 MYOM2 MIR181A1 IL6 IGHV4-38-2
8 osteosclerotic myeloma 30.2 MYOM2 IL6
9 leukemia, chronic myeloid 30.1 ITGB1 IRF4 IL6 CD38 CCND1
10 cervical cancer 30.1 TP73 FGFR3 CDKN2A CD44 CCND1
11 burkitt lymphoma 30.1 IRF4 IL6 ICAM1 CDKN2A CD44 CD40
12 castleman disease 30.0 SDC1 MYOM2 IL6
13 agammaglobulinemia 30.0 IRF4 IL6 CD40
14 cholangitis 30.0 IL6 ICAM1 CDKN2A
15 lymphoma, mucosa-associated lymphoid type 29.8 SDC1 IRF4 IGHV4-38-2 CD40 CCND1
16 squamous cell carcinoma 29.8 TP73 FGFR3 CDKN2A CD44 CCND1
17 b-cell lymphoma 29.8 IRF4 CDKN2A CD44 CD40 CCND3 CCND1
18 extramedullary plasmacytoma 29.8 SDC1 NCAM1 MYOM2 IRF4 IGHV4-38-2 CD38
19 marginal zone b-cell lymphoma 29.8 SDC1 IRF4 IGHV4-38-2 CD38 CCND1
20 lymphoma 29.8 ITGB1 IRF4 IL6 CDKN2A CD44 CD40
21 squamous cell carcinoma, head and neck 29.7 TP73 FGFR3 CDKN2A CD44 CCND1
22 head and neck cancer 29.7 MIR181A1 IL6 CDKN2A CD44 CCND1
23 peripheral nervous system disease 29.6 NCAM1 MYOM2 MIR181A1 IL6 ICAM1 CDKN2A
24 waldenstroem's macroglobulinemia 29.6 SDC1 MYOM2 IRF4 IGHV4-38-2 CD40 CD38
25 lymphoplasmacytic lymphoma 29.5 SDC1 MYOM2 IRF4 IGHV4-38-2 CD38 CCND1
26 skin disease 29.4 NCAM1 ITGB1 IL6 ICAM1 FGFR3 CDKN2A
27 monoclonal gammopathy of uncertain significance 29.3 SDC1 NSD2 NCAM1 MYOM2 MAF IRF4
28 acute promyelocytic leukemia 29.3 TP73 NCAM1 MIR181A1 ITGB1 IL6 ICAM1
29 prostate cancer 29.3 TP73 MIR181A1 ITGB1 IL6 ICAM1 FGFR3
30 leukemia, acute lymphoblastic 29.2 TP73 MIR181A1 IRF4 IGHV4-38-2 CDKN2A CD40
31 leukemia, chronic lymphocytic 29.1 SDC1 NCAM1 MIR181A1 IRF4 IL6 IGHV4-38-2
32 neuroblastoma 29.0 TP73 NCAM1 MIR181A1 ITGB1 IL6 CDKN2A
33 mantle cell lymphoma 29.0 SDC1 IRF4 IL6 IGHV4-38-2 CDKN2A CD44
34 leukemia, acute myeloid 28.9 SDC1 NCAM1 MIR181A1 IL6 IGHV4-38-2 CDKN2A
35 lymphoma, non-hodgkin, familial 28.8 SDC1 NCAM1 MIR181A1 IRF4 IL6 IGHV4-38-2
36 lymphatic malformation 1 11.1
37 hereditary lymphedema i 11.0
38 leukemia 10.8
39 post-traumatic stress disorder 10.6
40 hyperphenylalaninemia, bh4-deficient, a 10.6
41 cartilage disease 10.5
42 toe syndactyly, telecanthus, and anogenital and renal malformations 10.4
43 esophagus verrucous carcinoma 10.4 CDKN2A CCND1
44 hematologic cancer 10.4
45 lymphoproliferative syndrome 10.3
46 rheumatoid vasculitis 10.3 ICAM1 CD44
47 glass syndrome 10.3
48 tonsil squamous cell carcinoma 10.3 CDKN2A CCND1
49 chest wall lymphoma 10.3 IRF4 IGHV4-38-2
50 acute leukemia 10.3

Graphical network of the top 20 diseases related to Plasma Cell Leukemia:



Diseases related to Plasma Cell Leukemia

Symptoms & Phenotypes for Plasma Cell Leukemia

MGI Mouse Phenotypes related to Plasma Cell Leukemia:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 CCND1 CCND3 CD38 CD40 CD44 CDKN2A
2 neoplasm MP:0002006 10.27 CCND1 CCND3 CD44 CDKN2A FGFR3 ICAM1
3 endocrine/exocrine gland MP:0005379 10.27 CCND1 CCND3 CD38 CD40 CD44 CDKN2A
4 immune system MP:0005387 10.24 CCND1 CCND3 CD38 CD40 CD44 CDKN2A
5 cellular MP:0005384 10.22 CCND1 CD38 CD44 CDKN2A FGFR3 ICAM1
6 digestive/alimentary MP:0005381 10.09 CCND1 CD44 CDKN2A FGFR3 ICAM1 IL6
7 vision/eye MP:0005391 10.07 CCND1 CCND3 CD44 CDKN2A FGFR3 ICAM1
8 hematopoietic system MP:0005397 10.03 CCND1 CCND3 CD38 CD40 CD44 CDKN2A
9 respiratory system MP:0005388 9.92 CCND1 CCND3 CD44 CDKN2A FGFR3 IL6
10 mortality/aging MP:0010768 9.8 CCND1 CCND3 CD44 CDKN2A FGFR3 ICAM1
11 integument MP:0010771 9.32 CCND1 CD44 CDKN2A FGFR3 ICAM1 IL6

Drugs & Therapeutics for Plasma Cell Leukemia

Drugs for Plasma Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
2
Carmustine Approved, Investigational Phase 2 154-93-8 2578
3
Etoposide Approved Phase 2 33419-42-0 36462
4
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
5
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
6
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
8
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
9
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
10
Daratumumab Approved Phase 2 945721-28-8
11
Sodium citrate Approved, Investigational Phase 2 68-04-2 23431961
12
Ixazomib Approved, Investigational Phase 2 1072833-77-2 25183872
13
Pomalidomide Approved Phase 2 19171-19-8 134780
14
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
15
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
16
Elotuzumab Approved Phase 2 915296-00-3
17
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
18
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643
19
Allopurinol Approved Phase 2 315-30-0 2094 135401907
20
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
21
Acetaminophen Approved Phase 2 103-90-2 1983
22
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
23
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
24
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
25
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
26
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
27
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
28
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
29
Promethazine Approved, Investigational Phase 2 60-87-7 4927
30
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
31
Busulfan Approved, Investigational Phase 2 55-98-1 2478
32
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
34
Filanesib Investigational Phase 1, Phase 2 885060-09-3
35
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7 4897
36 BB 1101 Phase 2
37 Immunoglobulin A Phase 2
38 interferons Phase 2
39
Etoposide phosphate Phase 2 16760419
40 Antimitotic Agents Phase 2
41 Keratolytic Agents Phase 2
42 Tubulin Modulators Phase 2
43 Cyclosporins Phase 1, Phase 2
44 Liposomal doxorubicin Phase 2
45 Antiviral Agents Phase 2
46 Antineoplastic Agents, Hormonal Phase 2
47 Hormones Phase 2
48 Hormone Antagonists Phase 2
49 Antiemetics Phase 2
50 glucocorticoids Phase 2

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia Unknown status NCT01328236 Phase 2 Bortezomib;Liposome doxorubicin;Dexamethasone
2 Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies Unknown status NCT01435720 Phase 1, Phase 2
3 Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
4 Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft Completed NCT02556931 Phase 2 Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
5 A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00821249 Phase 1, Phase 2 ARRY-520, KSP(Eg5) inhibitor; intravenous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;Dexamethasone, steroid; oral
6 Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial Completed NCT00027820 Phase 1, Phase 2 Fludarabine Phosphate;Cyclosporine;Mycophenolate Mofetil
7 An Evaluation of Bortezomib (VelcadeR ) Followed by High-Dose Melphalan and Bortezomib (VelcadeR) as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants in Patients With Primary Refractory Multiple Myeloma and Plasma Cell Leukemia Completed NCT00307086 Phase 2 Bortezomib;Melphalan
8 A Pilot Study of Lenalidomide and Dexamethasone in Patients With Primary Plasma Cell Leukemia Completed NCT01553357 Phase 2 Lenalidomide, dexamethasone
9 Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70: Phase II Multicentre Study Completed NCT02858999 Phase 2 PAD-VCD
10 Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
11 Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases Recruiting NCT03314974 Phase 2
12 Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia Active, not recruiting NCT02547662 Phase 2 Dexamethasone;Ixazomib Citrate;Pomalidomide
13 Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Active, not recruiting NCT02506959 Phase 2 Busulfan;Gemcitabine Hydrochloride;Melphalan;Panobinostat
14 Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma Active, not recruiting NCT01729091 Phase 2 Lenalidomide;Melphalan
15 MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia. Active, not recruiting NCT03188172 Phase 2 Cyclophosphamide;Bortezomib;Lenalidomide;Daratumumab;Dexamethasone;Melphalan;Filgrastim
16 Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation : PCL-2 Study Not yet recruiting NCT05054478 Phase 2 Daratumumab
17 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32] Suspended NCT02661035 Phase 2 Allopurinol;Fludarabine;Cyclophosphamide;ATG;Tacrolimus;MMF
18 Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen Terminated NCT00615589 Phase 2 Fludarabine/Busulfan x 4 days
19 Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma Terminated NCT01658904 Phase 1, Phase 2 Carfilzomib;Melphalan;Filgrastim
20 Phase I-II Single Cycle Melphalan/Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) Followed by Maintenance in Patients With High-Risk Myeloma and/or Poor Response to Induction Therapy Within 12 Months of Diagnosis Withdrawn NCT03100877 Phase 1, Phase 2 Cyclophosphamide;Lenalidomide;Melphalan
21 A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients With Relapsed High-Risk Multiple Myeloma Completed NCT02504359 Phase 1 Carmustine;Cytarabine;Etoposide;Ixazomib Citrate;Melphalan;Methotrexate;Tacrolimus
22 A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Completed NCT01248923 Phase 1 ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Dexamethasone, steroid; oral;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
23 A Phase I Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma Completed NCT01372540 Phase 1 Carfilzomib;Filanesib
24 An Exploratory Study of Fully Human Anti-GPRC5D Chimeric Antigen Receptor T Cells (CAR-GPRC5D) in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT05219721 Phase 1 CAR-T (CAR-GPRC5D)
25 A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Active, not recruiting NCT02334865 Phase 1 Lenalidomide
26 Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma Active, not recruiting NCT01163357 Phase 1 bortezomib;fludarabine phosphate;tacrolimus;sirolimus
27 Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma Withdrawn NCT02315157 Phase 1 Bendamustine
28 Phase 1 Study of Daratumumab When Given in Combination With Bortezomib, Dexamethasone, Doxil, and Lenalidomide in Patients With Plasma Cell Leukemia Withdrawn NCT03591744 Phase 1 Bortezomib;Dexamethasone;Lenalidomide;Pegylated Liposomal Doxorubicin Hydrochloride
29 Phase II Open Lable Clinical Study Efficacy and Safety of the Holistic Treatment for Young Patients With High-Risk Multiple Myeloma Unknown status NCT04008888 Melphalan Given IV;Fludarabine Injection;PI and dexamethasone as maintenance therapy;PI+IMids+Dexamethasone as Consolidated Chemotherapy
30 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases Recruiting NCT01962636 Fludarabine;Cyclophosphamide;Cyclosporine A;Mycophenylate mofetil
31 Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry Recruiting NCT05556928
32 Registry for Adults With Plasma Cell Disorders (PCD's) Recruiting NCT03717844
33 A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH Recruiting NCT05283993
34 Individualized Treatment for Relapsed/Refractory Multiple Myeloma Based on High Throughput Drug Sensitivity and Genomics Data Recruiting NCT03389347
35 Expanded Access to Venetoclax Available NCT03123029 Venetoclax

Search NIH Clinical Center for Plasma Cell Leukemia

Cochrane evidence based reviews: leukemia, plasma cell

Genetic Tests for Plasma Cell Leukemia

Anatomical Context for Plasma Cell Leukemia

Organs/tissues related to Plasma Cell Leukemia:

MalaCards : Bone Marrow, Bone, Spleen, Liver, T Cells, Myeloid, Lymph Node

Publications for Plasma Cell Leukemia

Articles related to Plasma Cell Leukemia:

(show top 50) (show all 1212)
# Title Authors PMID Year
1
Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. 53 62
18231917 2008
2
Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells. 53 62
12017294 2002
3
Analysis of p73 and p53 gene deletions in multiple myeloma. 53 62
10602435 1999
4
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. 53 62
9844928 1998
5
Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma. 53 62
9369432 1997
6
Overexpression of PRAD1/cyclin D1 in plasma cell leukemia with t(11;14)(q13;q32). 53 62
9220667 1997
7
Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. 53 62
7524765 1994
8
Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. 53 62
7686332 1993
9
The establishment of an interleukin-6-dependent myeloma cell line (FLAM-76) carrying t(11;14)(q13;q32) chromosome abnormality from an aggressive nonsecretory plasma cell leukemia. 53 62
1516003 1992
10
Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. 53 62
1540875 1992
11
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. 53 62
1715218 1991
12
In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. 53 62
2060582 1991
13
Diagnosing Multiple Myeloma and Related Disorders. 62
36270842 2023
14
The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria. 62
35819882 2022
15
Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide. 62
35969250 2022
16
Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience. 62
35687847 2022
17
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party. 62
36404323 2022
18
How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells. 62
36450104 2022
19
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. 62
36315921 2022
20
[BILATERAL OCULAR PLASMACYTOMA PRESENTING AS ACUTE ANTERIOR UVEITIS]. 62
36315206 2022
21
Reversal of life-threatening bleeding with protamine sulfate in a patient with plasma cell leukemia. 62
35946464 2022
22
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. 62
35357885 2022
23
Primary plasma cell leukemia: what role does flow cytometry play? 62
36453736 2022
24
Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World. 62
35422411 2022
25
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study. 62
35987926 2022
26
Causes of death in primary plasma cell leukemia differ from multiple myeloma: A STROBE-compliant descriptive study based on SEER database. 62
35866755 2022
27
A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. 62
35840087 2022
28
Plasma cell leukemia presenting as spontaneous tumor lysis syndrome with hypercalcemia. 62
35846936 2022
29
Severe pulmonary toxicity related to carfilzomib use: a rare but serious side effect. 62
35787495 2022
30
A rare case of primary plasma cell leukemia exhibiting the small-cell variant of plasma cells. 62
35620908 2022
31
Double punch for plasma cell leukemia. 62
35770535 2022
32
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelling. 62
35770529 2022
33
Plasma cell leukemia: another piece of the puzzle. 62
35770536 2022
34
Plasma cell leukemia with small cell morphology. 62
35737405 2022
35
Plasma cell leukemia: Retrospective review of cases at Monter Cancer Center/Northwell Health Cancer Institute, 2014-2019. 62
35091270 2022
36
Update on primary plasma cell leukemia. 62
35483928 2022
37
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features. 62
35171994 2022
38
Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma. 62
36161295 2022
39
Adhesion molecules in multiple myeloma oncogenesis and targeted therapy. 62
35663420 2022
40
Genomics of Plasma Cell Leukemia. 62
35326746 2022
41
Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors. 62
35269460 2022
42
Coexistence of Acute Promyelocytic Leukemia and Primary Plasma Cell Leukemia: Careful Consideration in Diagnosis. 62
34635620 2022
43
A Rare Case of Plasma Cell Leukemia Presenting as Dyspnea. 62
35256091 2022
44
Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression. 62
35076333 2022
45
Electrolyte Abnormalities in a Man With Plasma Cell Leukemia. 62
35067318 2022
46
Plasma cell leukaemia with "lymphoid-like morphology" in peripheral blood. 62
33844877 2022
47
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma. 62
34592901 2022
48
Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation. 62
35982976 2022
49
Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy. 62
36212423 2022
50
[Descriptive cross-sectional study assessing the clinical and paraclinic profiles of monoclonal gammopathies in an agricultural region of Souss-Massa, Morocco]. 62
35371382 2022

Variations for Plasma Cell Leukemia

Expression for Plasma Cell Leukemia

Search GEO for disease gene expression data for Plasma Cell Leukemia.

Pathways for Plasma Cell Leukemia

Pathways related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 CCND1 CD40 CD44 ICAM1 IL6 IRF4
2
Show member pathways
12.77 TP73 IL6 CD40 CCND3 CCND1
3
Show member pathways
12.63 SDC1 NCAM1 ITGB1 ICAM1 CD44
4
Show member pathways
12.46 NCAM1 IRF4 ICAM1 CD44
5 12.43 TP73 CDKN2A CCND3 CCND1
6
Show member pathways
12.14 ITGB1 FGFR3 CCND3 CCND1
7 12.14 CCND1 CD40 CDKN2A IRF4
8 12.11 ITGB1 IL6 FGFR3 CDKN2A CD44 CCND3
9
Show member pathways
12.08 NCAM1 ITGB1 ICAM1 CD44
10 11.87 IL6 CDKN2A CD44
11 11.85 TP73 CCND3 CCND1
12 11.83 ITGB1 CDKN2A CD44 CCND1
13 11.81 SDC1 NCAM1 ITGB1 ICAM1 CD44
14
Show member pathways
11.8 IRF4 IL6 ICAM1
15
Show member pathways
11.79 FGFR3 CD44 CCND1
16 11.72 CCND1 CDKN2A MAF
17 11.72 CD44 IRF4 NCAM1
18 11.72 SDC1 NCAM1 IL6 CD44 CD38
19 11.71 NCAM1 FGFR3 CD44
20 11.68 IL6 ICAM1 FGFR3
21 11.66 FGFR3 CDKN2A CCND1
22 11.64 IRF4 IL6 CD40
23 11.61 MIR181A1 CCND3 CCND1
24 11.6 TP73 CDKN2A CCND3
25 11.6 NCAM1 IRF4 IL6 CD38
26 11.59 ITGB1 IRF4 IL6 ICAM1 CCND1
27
Show member pathways
11.57 IL6 ICAM1 CCND1
28 11.55 CDKN2A CCND3 CCND1
29 11.54 MAF IL6 CDKN2A CCND1
30 11.49 IL6 CD44 CCND1
31 11.33 FGFR3 CDKN2A CCND1
32 11.3 NCAM1 ITGB1 CD44
33 11.26 SDC1 ITGB1 CD44
34 11.23 IL6 CDKN2A CCND1
35 11.21 IL6 CCND3 CCND1
36 11.03 NCAM1 ITGB1 CCND1
37 11 SDC1 NCAM1 ITGB1 IL6 CD44

GO Terms for Plasma Cell Leukemia

Cellular components related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.77 SDC1 NCAM1 ITGB1 IGHV4-38-2 IGHG1 ICAM1
2 cell surface GO:0009986 9.53 SDC1 NCAM1 ITGB1 ICAM1 FGFR3 CD44

Biological processes related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.63 CDKN2A CCND3 CCND1
2 T-helper 17 cell lineage commitment GO:0072540 9.26 IRF4 IL6
3 regulation of cell cycle GO:0051726 9.23 TP73 ITGB1 CDKN2A CCND3 CCND1

Sources for Plasma Cell Leukemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....